Basilea Pharmaceutica AG (BPMUF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Basilea Pharmaceutica AG (BPMUF) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. La acción obtiene una puntuación de 58/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 17 mar 2026Basilea Pharmaceutica AG (BPMUF) Resumen de Asistencia Médica y Tuberías
Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company specializing in oncology and anti-infectives, offering treatments like Cresemba and Zevtera. With a 17.9% profit margin and a beta of 0.46, the company focuses on addressing unmet medical needs through ongoing clinical trials and strategic product development within the biotechnology sector.
Tesis de Inversión
Basilea Pharmaceutica AG presents a compelling investment case due to its established products and promising pipeline. With a market capitalization of $0.87 billion and a P/E ratio of 19.42, the company demonstrates financial stability and growth potential. Key value drivers include the continued commercial success of Cresemba and Zevtera, as well as the advancement of Derazantinib and Lisavanbulin through clinical trials. The company's 74.3% gross margin indicates strong pricing power and efficient operations. Upcoming clinical trial results and potential regulatory approvals for its pipeline candidates serve as significant growth catalysts. However, potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market Cap of $0.87 billion reflects investor confidence in Basilea's pipeline and commercial products.
- P/E ratio of 19.42 indicates a reasonable valuation compared to its earnings.
- Profit Margin of 17.9% demonstrates efficient operations and profitability.
- Gross Margin of 74.3% showcases strong pricing power and cost management.
- Beta of 0.46 suggests lower volatility compared to the overall market, making it a potentially stable investment.
Competidores y Pares
Fortalezas
- Specialized expertise in oncology and anti-infectives.
- Commercialized products with established revenue streams.
- Promising pipeline of drug candidates in clinical trials.
- Strong gross margin.
Debilidades
- Reliance on a limited number of products.
- High R&D expenses.
- Dependence on regulatory approvals.
- Competition from larger pharmaceutical companies.
Catalizadores
- Upcoming: Phase III clinical trial results for Cresemba in Japan for invasive fungal infections.
- Upcoming: Phase III clinical trial results for Zevtera in acute bacterial skin and skin structure infections and Staphylococcus aureus bacteremia.
- Ongoing: Phase 2 clinical trial progress for Derazantinib in bile duct cancer.
- Ongoing: Phase ½ clinical trial progress for Derazantinib in bladder and stomach cancer.
- Ongoing: Development progress of Lisavanbulin as a tumor checkpoint controller drug.
Riesgos
- Potential: Clinical trial failures for drug candidates.
- Potential: Regulatory delays or rejections.
- Ongoing: Competition from established pharmaceutical companies.
- Ongoing: Patent expirations and generic drug entry.
- Potential: Product liability claims.
Oportunidades de crecimiento
- Expansion of Cresemba's Market Reach: Cresemba, Basilea's antifungal drug, has the potential for significant growth through geographic expansion and label extensions. The global market for antifungal drugs is projected to reach $17.5 billion by 2028. Securing regulatory approvals in additional markets, such as Japan, and expanding its use to treat other fungal infections could drive substantial revenue growth for Basilea.
- Advancement of Derazantinib in Oncology: Derazantinib, a small molecule inhibitor, is currently in Phase 2 clinical trials for bile duct cancer and Phase ½ clinical trial for bladder and stomach cancer. The oncology market is one of the largest and fastest-growing segments in the pharmaceutical industry. Positive clinical trial results and subsequent regulatory approval could position Derazantinib as a valuable asset in Basilea's oncology portfolio, addressing a significant unmet medical need.
- Development of Lisavanbulin as a Tumor Checkpoint Controller: Lisavanbulin, a tumor checkpoint controller drug, represents a novel approach to cancer treatment. The market for immunotherapies and checkpoint inhibitors is experiencing rapid growth. Successful development and commercialization of Lisavanbulin could provide Basilea with a competitive advantage in the oncology space, capturing a significant share of the immunotherapy market.
- Lifecycle Management of Zevtera: Zevtera, Basilea's antibiotic, is currently in Phase III clinical trials for acute bacterial skin and skin structure infections and Staphylococcus aureus bacteremia. Expanding the indications for Zevtera through successful clinical trials and regulatory approvals can extend its market exclusivity and drive revenue growth. The increasing prevalence of antibiotic-resistant bacteria underscores the need for new and effective antibiotics, creating a favorable market environment for Zevtera.
- Strategic Partnerships and Acquisitions: Basilea can pursue strategic partnerships and acquisitions to expand its pipeline and market reach. Collaborating with other biotechnology and pharmaceutical companies can provide access to new technologies, drug candidates, and markets. Acquiring complementary assets can strengthen Basilea's competitive position and accelerate its growth trajectory. These strategic initiatives can enhance Basilea's long-term value and create synergies across its operations.
Oportunidades
- Expansion into new geographic markets.
- Development of new drug candidates.
- Strategic partnerships and acquisitions.
- Lifecycle management of existing products.
Amenazas
- Clinical trial failures.
- Regulatory hurdles.
- Competition from generic drugs.
- Patent expirations.
Ventajas competitivas
- Patented pharmaceutical products.
- Specialized expertise in oncology and anti-infectives.
- Established distribution network.
- Strong brand reputation.
Acerca de BPMUF
Founded in 2000 and headquartered in Basel, Switzerland, Basilea Pharmaceutica AG is a biopharmaceutical company dedicated to developing and commercializing innovative products that address critical medical needs in oncology and anti-infectives. The company's portfolio includes Cresemba, an intravenous and oral azole antifungal drug used to treat invasive aspergillosis and mucormycosis. Cresemba is available in the United States and the European Union, and is currently in Phase III clinical trials in Japan for invasive fungal infections. Another key product is Zevtera, an antibiotic used for treating community and hospital-acquired pneumonia. Zevtera is also undergoing Phase III clinical trials for acute bacterial skin and skin structure infections, as well as Staphylococcus aureus bacteremia. Basilea is also developing Derazantinib, a small molecule inhibitor in Phase 2 clinical trial for bile duct cancer and Phase ½ clinical trial for bladder and stomach cancer. Additionally, they are developing Lisavanbulin, a tumor checkpoint controller drug. Basilea's strategic focus on these therapeutic areas positions it to capitalize on the growing demand for novel treatments in oncology and infectious diseases.
Qué hacen
- Develop and commercialize pharmaceutical products.
- Focus on oncology and anti-infectives therapeutic areas.
- Offer Cresemba for the treatment of invasive aspergillosis and mucormycosis.
- Provide Zevtera for the treatment of community and hospital-acquired pneumonia.
- Engage in clinical trials for new drug candidates.
- Develop Derazantinib for bile duct, bladder, and stomach cancer.
- Develop Lisavanbulin as a tumor checkpoint controller drug.
Modelo de Negocio
- Develop and license pharmaceutical products.
- Generate revenue through product sales.
- Invest in research and development to expand product pipeline.
- Partner with other companies for commercialization and distribution.
Contexto de la Industria
Basilea Pharmaceutica AG operates within the biotechnology industry, which is characterized by rapid innovation and high regulatory scrutiny. The market for anti-infectives and oncology drugs is substantial and growing, driven by an aging population and increasing prevalence of chronic diseases. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share. Basilea differentiates itself through its focus on specific therapeutic areas and its pipeline of novel drug candidates. The biotechnology industry is expected to continue its growth trajectory, fueled by advancements in genomics, personalized medicine, and drug delivery technologies.
Clientes Clave
- Hospitals and healthcare providers.
- Patients with fungal infections and pneumonia.
- Oncology patients.
- Pharmaceutical distributors.
Finanzas
Gráfico e información
Precio de la acción de Basilea Pharmaceutica AG (BPMUF): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para BPMUF.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para BPMUF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para BPMUF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de BPMUF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: David Veitch
CEO
David Veitch serves as the CEO of Basilea Pharmaceutica AG, bringing extensive experience in the pharmaceutical industry. His career spans various leadership roles in commercial operations, strategic planning, and business development. He has a proven track record of driving growth and innovation in the healthcare sector. His expertise lies in leading global teams and successfully launching pharmaceutical products in competitive markets. Veitch's background includes significant contributions to the development and commercialization of novel therapies.
Historial: Under David Veitch's leadership, Basilea Pharmaceutica AG has focused on expanding its pipeline and strengthening its commercial presence. Key milestones include advancing clinical trials for Derazantinib and Lisavanbulin, as well as optimizing the market performance of Cresemba and Zevtera. He has also emphasized strategic partnerships to enhance the company's growth prospects and market reach.
Información del mercado OTC de BPMUF
The OTC Other tier represents the lowest tier of the OTC market, indicating that Basilea Pharmaceutica AG (BPMUF) may not meet the minimum financial or disclosure requirements of the higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no reporting requirements, which increases investment risk. Trading on the OTC Other market differs significantly from exchanges like NYSE or NASDAQ, which have stringent listing standards and reporting obligations. Investors should exercise caution and conduct thorough due diligence before investing in companies on this tier.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited Disclosure: Lack of comprehensive financial reporting increases information asymmetry.
- Low Liquidity: Difficulty in buying or selling shares without affecting the price.
- Price Volatility: Higher price fluctuations due to lower trading volumes.
- Regulatory Scrutiny: Potential for regulatory actions due to non-compliance.
- Going Concern Risk: Increased risk of financial distress or bankruptcy.
- Verify the company's financial statements and audit reports.
- Assess the company's management team and their track record.
- Research the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Check for any red flags or warning signs.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Established Products: Commercialized products like Cresemba and Zevtera indicate a viable business.
- Clinical Trials: Ongoing clinical trials suggest continued investment in research and development.
- Experienced Management: Presence of an experienced CEO like David Veitch.
- Partnerships: Strategic alliances with other companies can validate the business model.
- Scientific Publications: Peer-reviewed publications supporting their research.
BPMUF Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar BPMUF?
Basilea Pharmaceutica AG (BPMUF) actualmente tiene una puntuación IA de 58/100, indicando puntuación moderada. Fortaleza clave: Specialized expertise in oncology and anti-infectives.. Riesgo principal a monitorear: Potential: Clinical trial failures for drug candidates.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de BPMUF?
BPMUF actualmente puntúa 58/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de BPMUF?
Los precios de BPMUF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre BPMUF?
La cobertura de analistas para BPMUF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en BPMUF?
Las categorías de riesgo para BPMUF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Clinical trial failures for drug candidates.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de BPMUF?
La relación P/E para BPMUF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está BPMUF sobrevalorada o infravalorada?
Determinar si Basilea Pharmaceutica AG (BPMUF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de BPMUF?
Basilea Pharmaceutica AG (BPMUF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide additional insights.